Patients and Methods
A new AS protocol mandating image-guided baseline biopsies, annual mpMRI and 3-monthly prostate-specific antigen (PSA) testing, but which retained protocol rebiopsies, was tested. Pathological progression, treatment conversion and triggers for non-protocol biopsy were recorded prospectively.
Results
Data from 157 men enrolled in the AS protocol (median age 64 years, PSA 6.8 ng/mL, follow-up 39 months) were interrogated. A total of 12 men (7.6%) left the AS programme by choice. Of the 145 men who remained, 104 had rebiopsies either triggered by a rise in PSA level, change in mpMRI findings or by protocol. Overall, 23 men (15.9%) experienced disease progression; pathological changes were observed in 20 men and changes in imaging results were observed in three men. Of these 23 men, 17 switched to treatment, giving a conversion rate of 11.7% (<4% per year). Of the 20 men with pathological progression, this was detected in four of them after a PSA increase triggered a re-biopsy, while in 10 men progression was detected after an mpMRI change. Progression was detected in six men, however, solely after a protocol re-biopsy without prior PSA or mpMRI changes. Using PSA and mpMRI changes alone to detect progression was found to have a sensitivity and specificity of 70.0% and 81.7%, respectively.
Introduction
The incidence of low-risk prostate cancer in the UK has grown rapidly in recent years with the increased uptake of PSA testing [1] . Randomized trials have failed to show any disease-specific or overall survival benefit from treating men with low-risk prostate cancer by radical therapy in comparison to conservative management [2, 3] ; therefore, the National Institute for Health and Care Excellence (NICE) and other guideline bodies have recommended active surveillance (AS) as a valid therapy option for men with low-risk prostate cancer [4] . A number of studies have now reported excellent outcomes from AS, with systematic reviews concluding that AS is a safe and effective form of management [5, 6] . Despite this, AS still has high early attrition rates and there is significant debate about the optimal follow-up regime [7] [8] [9] .
Multiparametric MRI (mpMRI) is now an essential tool in initial staging as well as tumour identification [8] . It is also now well recognized that many cancers are misclassified on first biopsy, and repeat sampling can result in upgrading in up to 35% of cases amongst non-targeted cohorts [10, 11] . mpMRI has therefore become an important tool in appropriate baseline selection for AS and in its follow-up [12] [13] [14] ; however, the optimal imaging schedule for mpMRI during AS is yet to be defined, with current UK 2014 guidelines only advising mpMRI at AS enrolment, without defining a protocol for subsequent scans [4] .
Current unanswered questions in AS management are therefore whether (i) mpMRI-improved baseline risk stratification provides clinical benefit in reducing treatment conversion rates and (ii) how effective mpMRI is in detecting progression and whether this could negate the need for routine protocol-based re-biopsies. To address these knowledge gaps we trialled a new AS protocol in our unit in 2011 that mandated early biopsy re-assessment and annual mpMRI. To assess the pathological progression rates comprehensively, we included image-guided and systematic biopsies at the outset and in subsequent scheduled interval re-biopsies. In the present paper, we report the early outcomes of this protocol.
Patients and Methods

Study Cohort
Newly diagnosed patients selecting AS as their preferred management were recruited from 2011 onwards into a prospective study at our institution (Cambridge University Hospital Trust, Cambridge, UK; registration number: 3592). Eligibility was restricted to men aged 50-80 years with histologically proven prostate adenocarcinoma, clinical stage T1-T2, PSA ≤20 ng/mL, histological Grade Group ≤2 and <50% overall tumour core involvement and who were otherwise medically fit for radical treatment options (Eastern Cooperative Oncology Group performance status 0 or 1). All men were treatment-na€ ıve with a first diagnosis of cancer. Our standard diagnostic pathway during the study period was 12-core sectoral transrectal prostate biopsy. A baseline mpMRI was performed at AS entry with the mpMRI used to guide a subsequent early transperineal re-biopsy performed using image-fusion software as previously reported [15] .
Where no lesion was identified, standard sectoral biopsies were performed. The only exceptions were men who had already had previous negative biopsies and those first diagnosed using a transperineal image-fusion method (Table 1) . Identification of higher-risk tumours from an early re-biopsy mandated assignment to treatment unless the patient was very keen to remain on AS. For the purposes of the present study, only men with a minimum of 12 months' clinical follow-up were included.
Active Surveillance Follow-Up
After baseline assessment as above, the protocol incorporated 3-monthly PSA testing, annual repeat mpMRI, and scheduled protocol interval re-biopsy at 12 months after completing baseline assessment and then at year 3. Outpatient review was performed annually (Fig. 1) . Three consecutive rises in PSA level or a reported change in mpMRI results (increase in number of lesions, increase in lesion size or stage progression) triggered an earlier targeted image-fusion rebiopsy. Two cores were taken from target lesions in addition to two cores from each of 12 anatomical sectors [15] . Progression on AS was defined as pathological progression on a re-biopsy or progression on mpMRI from T2 to T3. Pathological progression was defined as a Grade Group increase between diagnostic and repeat biopsy. In all cases of progression, ongoing participation in AS or conversion to treatment was re-discussed.
Multiparametric MRI
All mpMRI was performed on a 3-T Discovery MR750-HDx or 1.5-T MR450 system (GE Healthcare, Waukesha, WI, USA) with a surface phased-array coil, including standard anatomical and functional diffusion-weighted imaging using multiple b-values, as previously described [16] . Images were reported by expert uro-radiologists and reviewed in a multidisciplinary team setting. A reported lesion (score of ≥3 on a Likert scale) of any size on baseline imaging was considered an MRI-positive lesion for the purposes of subsequent analysis. The present study predated the PRECISE grading criteria, however, for consistency, a five-point Likert scale was prospectively used throughout the study period, informed by Prostate Imaging -Reporting and Data System (PI-RADS) versions 1 and 2 after their publication, with a score ≥3 considered suspicious [17, 18] . For the purposes of robust assessment of this protocol, re-biopsies were carried out using a transperineal approach, with image-guided and systematic biopsies when suspicious lesions were present on mpMRI. Men with no lesion on mpMRI underwent systematic biopsies only (transperineal or transrectal). All mpMRI changes and re-biopsy results were reviewed and discussed in multidisciplinary team meetings before a change in the AS pathway was triggered.
Statistical Analysis
The measured outcomes were patient adherence to AS, pathological progression and rates of conversion to treatment. The ability to use PSA and mpMRI changes to detect all progression events was compared with assessment of the outcomes from re-biopsies conducted at the protocol intervals (considered the reference standard for the present study). Data from men who were scheduled to undergo protocolbased re-biopsies but declined the procedure were kept in the analysis to allow overall assessment of progression. KaplanMeier curves were used to describe treatment-free and progression-free survival outcomes. Time was measured from date of enrolment in AS, and censored at date of last followup. Cox regression analyses were performed to calculate hazard ratios with 95% CIs to explore predictors of time to progression and conversion to treatment. All available clinical variables were included in a first pass analysis. P values <0.05
were taken to indicate statistical significance. As no variables showed a significant association this was not developed further. Statistical analysis was performed using STATA 14 (College Station, TX, USA).
Results
Baseline Cohort Characteristics
A total of 157 men were managed using the AS protocol and met minimum follow-up criteria (Fig. 2 ). Of these, only 12 (7.6%) dropped out of the AS programme, by choice. The baseline cohort characteristics of the remaining 145 men are shown in Table 1 (Table 2) . A total of 41 men declined any repeat further re-biopsies.
Pathological Progression and Conversion to Treatment
Of the 145 men who stayed on AS, 23 men had disease progression over the median follow-up of 39 months, equating to an overall progression rate of 15.9%. In 20 men this was attributable to a pathological upgrade after either a protocol or triggered re-biopsy. Three additional patients with known Grade Group 2 disease had stage progression from T2 to T3 on mpMRI and converted to radiotherapy treatment without repeat biopsy or further evaluable histology. Details of these men are shown in Table 3 . If we consider pathological progression only in those men who underwent further re-biopsies within the present study, the progression rate was 19.2%. Of the 23 men with disease progression, 17 chose to convert to active treatment, and six others with only Grade Group changes elected to stay on AS. This resulted in an annual conversion rate of <4% per year, Only five men converted to treatment within the first 24 months, equating to an overall treatment-free survival of 96.6% at 2 years.
Among the 20 men with pathological progression, six were detected by interval protocol re-biopsy with no prior increase in PSA or change in mpMRI characteristics. mpMRI changes, prompting a non-protocol biopsy, accounted for half of detected upgrading (n = 10). Notably, however, in 10 further men, changes in mpMRI triggered a re-biopsy yet did not identify disease upgrading. Eight of these men were found to have disease of the same grade on re-biopsy, whereas the remaining two men had benign biopsies. In all these cases the Table 4 shows the sensitivity, specificity and predictive values of this approach, among only those men who underwent repeat biopsies (n = 104). The sensitivity and specificity of using mpMRI and PSA assessment were 70% and 81.7%, respectively. Of the 17 men who converted to active treatment, two underwent robotassisted laparoscopic prostatectomy. The remaining 15 men opted for radiotherapy and/or androgen deprivation therapy alone.
Subgroup analysis was performed on the 10 men diagnosed with pathological progression after MRI changes. In five out of 10 cases, upgrades were from mpMRI-defined targeted areas, and in two cases, although the targeted biopsy was unchanged/negative, an upgrade was found in an adjacent sector. In the remaining three cases, upgrades were in areas remote from the target.
The associations between different variables and AS progression are shown in Tables S1A and B. Prior negative biopsy before diagnosis demonstrated a non-significant trend to lower rates of AS progression in both univariate (hazard ratio 0.40, 95% CI 0.15-1.08; P = 0.07) and multivariate analysis (hazard ratio 0.37, 95% CI 0.13-1.07; P = 0.06).
Discussion
In the present paper, we report the early outcomes from a prospectively applied structured AS regimen incorporating image-guided baseline risk assessment and mpMRI-based follow-up. Conversion to treatment through patient choice in this study was 7.6% over a median 3.3 years of follow-up.
This compares very favourably with published drop-out rates of up to 36% over similar follow-up periods in other contemporary series [19] . Only 11.7% of men in our series converted to treatment during AS. Over similar follow-up periods, 33% converted to treatment in the Johns Hopkins Series (median follow-up 2.7 years) [20] , 25% in the University of Miami series (2.9 years median follow-up) [21] , 32% in the European Randomized Study of Screening for Prostate Cancer (ERSPC) series (3.9 years follow-up) [22] and, in the largest published UK study, 20% of men in the Royal Marsden series converted to treatment over just 1.8 years of follow-up [23] . Notably, these series did not include baseline MRI risk stratification. These differences may be explained by stricter baseline assessment prior to inclusion in our series, with more conversions to treatment after early reclassification in older series. A number of publications have previously shown that image-guided biopsies by any route are good at detecting disease, including in the context of selecting men for AS [24] [25] [26] .
One of our key questions was how good mpMRI was in detecting pathological progression as a non-invasive monitoring tool. This was referenced against a comprehensive baseline biopsy assessment and using the same assessment in interval re-biopsies. In our cohort this was evaluable in the 104 men who did have a repeat biopsy, either through the protocol or when triggered by a PSA rise or mpMRI change. This detected 20 pathological progressions. Half of these were first detected by an MRI change and then confirmed on biopsies without a concomitant alteration in PSA levels. In this respect, mpMRI proved very good at detecting changes translating into a disease upgrade; however a number of reported changes in mpMRI findings did not show pathological upgrading on rebiopsy and this affected the overall sensitivity and specificity of imaging as a stand-alone AS tool (Table 3 ). This may of course be attributable to biopsy sampling errors and will probably improve with evolving MRI protocols and better hardware and software [15, 27] . Our recent adoption (in 2016) of the standardized PRECISE reporting tool, for example, may also improve future consistency in reporting [17] . For the present, however, our data support the conclusions from a recent systematic review which suggested that change in mpMRI findings should not itself drive a change to treatment but instead trigger re-biopsy because of the possibility that there is no true pathological change [14] . Whether re-biopsy in this context should be targeted alone, or systematic and targeted is another unanswered question in AS follow-up. In the small subcohort of 10 men with pathological progression after mpMRI-detected changes in the present study, only five upgrades were detected on targeted cores, with upgrade detected in areas remote from the target in three cases. Further study is required in this area but these results suggest a combination of systematic Cases where no re-biopsy occurred within the study period were excluded from this analysis (n = 104).
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Our data do raise the possibility that mpMRI-based surveillance might result in more re-biopsies than a programme that relied only on PSA changes to trigger reinvestigation, particularly in centres where MRI reading and reporting is evolving. PSA changes alone found upgrading in four men in the present cohort, but also led to a similar number having biopsies with no change in pathology.
Nearly a third of pathological progressions were detected by scheduled protocol biopsies without evidence of an mpMRI or PSA change. This echoes the recent findings of Ma et al. [29] from Johns Hopkins who reviewed the results of 157 men who had template and systematic biopsies within an AS programme, and concluded that systematic re-biopsies were still needed in AS given the relatively low sensitivity of mpMRI in this context. Further work is needed in larger multicentre trials to determine the true benefit and impact of mpMRI use in AS pathways before widespread adoption in national guidelines. For the present, our data suggest that PSA tests, mpMRI and protocol re-biopsy are all important contributing parts of an AS programme to detect early pathological progression. The importance of detecting early grade progression is of course debatable, as is the significance of detecting increased core involvement or core positivity. There is no current national or international standard on this, and grade progression remains a key marker of progression in AS [30] .
One significant factor in the present study is that a number of men declined invitation for scheduled interval re-biopsies during AS. In clinic consultations we found that many men take great reassurance from an unchanged annual mpMRI and stable PSA. This further reinforces the need for future research to embed standardized mpMRI reporting and assess how safe it is to omit protocol biopsies as routine practice.
As our cohort size was relatively small and with a short follow-up, it is perhaps unsurprising that we failed to find many predictors of progression or conversion to treatment. Neither a positive mpMRI lesion nor an initial Grade Group 2 diagnosis predicted progression or conversion to active treatment which is in contrast to other studies [31] [32] [33] . We did observe that men with a previous negative biopsy appeared less likely to progress, which supports the findings of a recent large Danish study that reported extremely low rates of prostate cancer mortality [0.7-3.6%] from a retrospective database review of men with first negative biopsies over a 20-year follow-up period, underscoring the indolent nature of many of these tumours [34] .
The present study has some limitations. Adherence to our re-biopsy protocol was incomplete, with a number of men not undergoing any additional biopsies within our follow-up period. Compliance with AS protocols, however, is known to be a universal problem in the published literature. In the PRIAS study, for example, only 30% of men were still adherent to the protocol after 4 years of AS [35] . This was attributed to issues from both patients and clinicians [35] . The present study also had relatively short follow-up and we cannot say if our protocol will materially alter survival rates. Indeed this is an unknown factor in almost all contemporary AS protocols. As mentioned, our imaging reports did not include standardized reporting until 2016, and we are continuing to review if this will have an impact on triggers for re-biopsy. Re-biopsies did use an image-guided fusion approach, but there remains a possibility of sampling errors. Our protocol is also 'investigation-heavy' in that men underwent annual MRI and image-guided and systematic biopsies. We do not claim, therefore, that this should be the adopted standard, instead we have used this protocol to test the value of MRI at baseline and in follow-up to inform future safer and less intensive regimens. Future work to verify our findings, and to further refine the protocol (extending mpMRI and biopsy intervals) is currently underway. Finally, as this was not a clinical trial, we did not mandate central review or double-reading of imaging or biopsies. All results were discussed in team multidisciplinary meetings, however, thus reflecting real-world practice.
In summary, we have reported the early outcomes of a structured AS protocol using mpMRI as a surveillance tool after thorough image-guided baseline assessment in men with favourable-risk disease. Our data suggest low patient choice drop-out rates and treatment conversions in men optimally selected for AS. mpMRI is the primary trigger for detecting disease progression on re-biopsy but can miss some pathological progressions, suggesting that protocol re-biopsy should not yet be abandoned. Our results suggest the need for multicentre trials to assess the true impact of an imagebased AS protocol with regard to clinical and patient benefit and with respect to health economic implications among men with favourable-risk prostate cancer. This is particularly important as clinicians and patients are already increasingly using imaging as a primary surveillance tool. 
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